FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
Ontology highlight
ABSTRACT: The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin), with the EGF receptor antibody cetuximab (Erbitux) in first-line treatment of metastatic colorectal cancer. The trial will investigate two regimens of FLOX plus cetuximab, in which FLOX is given continuously or intermittently, compared to standard FLOX without cetuximab.
DISEASE(S): Patient With Metastatic Colorectal Cancer.,Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2015398 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA